title: Characteristics of fluvoxamine-induced nausea.
abstract: We investigated the association between fluvoxamine and nausea from various viewpoints. The incidence of nausea induced by fluvoxamine was 29% (12/41). Plasma 5-hydroxyindoleacetic acid (p5-HIAA) levels after fluvoxamine administration were significantly higher in patients with nausea (6.6+/-3.4 ng/ml) than in those without nausea (3.5+/-2.7 ng/ml). On the other hand, no significant differences were found between patients with and patients without nausea in terms of sex, age, initial and maximum dosages of fluvoxamine and its plasma concentrations, and clinical response to fluvoxamine. However, the incidence of nausea in patients who were initially administered fluvoxamine at under 50 mg/day was significantly lower than in those who were started at above 50 mg/day. In addition, mosapride, a member of the benzamide family, was effective in alleviating fluvoxamine-induced nausea. These results suggest that fluvoxamine-induced nausea is associated with hyperactivity in serotonergic neurons.
authors.affiliation: Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanisi-ku, Kitakyusyu, Fukuoka, 807-8555, Japan. ezd04735@nifty.ne.jp
authors.forename: N
authors.initials: N
authors.lastname: Ueda
authors.forename: R
authors.initials: R
authors.lastname: Yoshimura
authors.forename: K
authors.initials: K
authors.lastname: Shinkai
authors.forename: T
authors.initials: T
authors.lastname: Terao
authors.forename: J
authors.initials: J
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced* / Q000175:diagnosis* / Q000188:drug therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000932:Antiemetics; D001549:Benzamides; D016666:Fluvoxamine; D006897:Hydroxyindoleacetic Acid; D009025:Morpholines; D017367:Selective Serotonin Reuptake Inhibitors; C062720:mosapride